The subsidiary of Lepu Medical Technology (300003.SZ) intends to grant a paid license for the MWN105 injection to Denmark's Sidera.

Lepu Medical Technology (300003.SZ) announced that its subsidiary Shanghai Minwei Bio has granted a paid license of the self-owned intellectual property MWN105 injection to Danish company Sidera. Sidera will have exclusive rights for development and commercialization in the global market outside of Greater China (Mainland China, Hong Kong, Macau, and Taiwan). As part of the license transaction, Shanghai Minwei Bio will acquire 9.99% of Sidera's equity and receive licensing fees for MWN105 injection. A total of 35 million US dollars will be paid as the initial investment and milestone payments. Shanghai Minwei Bio will also acquire 9.99% equity of Sidera as part of the license transaction. Depending on clinical development and sales revenue, Sidera will pay Shanghai Minwei Bio up to a total of 1.01 billion US dollars in milestone payments. Shanghai Minwei Bio has the right to receive sales royalties from Sidera based on actual net sales annually (excluding Mainland China, Hong Kong, Macau, and Taiwan).